Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Christophe Louvet

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2240-4706; OpenAlex author ID A5002063921. Sources: ClinicalTrials.gov.

Their work

Papers
20 (first author 0, last author 3)
Trials
4
Grants
0
Labs led
1
Collaborators
64
Papers, trials and grants by year

1999: 2 trials · 2000: none · 2001: none · 2002: none · 2003: 1 trial · 2004: 1 trial · 2005: none · 2006: none · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 3 papers · 2013: 2 papers · 2014: none · 2015: 2 papers · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 20

  1. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  2. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  3. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  4. Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2020.08.016↗
  5. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized … Co-author DOI 10.1016/j.ejca.2019.10.020↗
  6. Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label,… Co-author DOI 10.1016/j.ejca.2020.02.004↗
  7. Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leu… Co-author DOI 10.1002/cam4.2311↗
  8. [Olaparib and pancreatic cancer: A challenging Lesson]. Co-author DOI 10.1016/j.bulcan.2019.07.002↗
  9. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR)… Last author DOI 10.1016/s2468-1253(17)30046-8↗
  10. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/jnci/djx037↗
  11. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Wi… Last author DOI 10.1001/jama.2016.4324↗
  12. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer. Co-author DOI 10.1016/j.molonc.2016.01.006↗
  13. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Co-author DOI 10.1038/bjc.2016.212↗
  14. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-0667↗
  15. A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer:… Last author DOI 10.1186/s12885-015-1656-4↗
  16. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2013.04.017↗
  17. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Co-author DOI 10.1093/annonc/mdt176↗
  18. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Co-author DOI 10.1053/j.gastro.2012.06.006↗
  19. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
  20. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr617↗

Trials 4

  1. Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Study chair NCT00268411↗
  2. Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma NCT00075452↗
  3. Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Study chair NCT00006117↗
  4. Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct Study chair NCT00010088↗

Closest collaborators

The 25 strongest of 64 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pascal R. Hammel · 15 shared papers, 2012–2026 · strength 0.96
  2. Jean‐Baptiste Bachet · 13 shared papers, 2012–2026 · strength 0.87
  3. Thierry André · 11 shared papers, 2012–2026 · strength 0.71
  4. Christophe Tournigand · 6 shared papers, 2017–2026 · strength 0.57
  5. Jerome F. Cros · 5 shared papers, 2013–2026 · strength 0.46
  6. Déwi Vernerey · 4 shared papers, 2016–2026 · strength 0.45
  7. Franck Bonnetain · 8 shared papers, 2012–2019 · strength 0.39
  8. Christelle de la Fouchardière · 3 shared papers, 2020–2026 · strength 0.39
  9. Isabelle Trouilloud · 2 shared papers, 2021–2026 · strength 0.34
  10. Olivier Bouché · 5 shared papers, 2013–2020 · strength 0.31
  11. Cindy Neuzillet · 2 shared papers, 2017–2026 · strength 0.28
  12. Benoı̂t Rousseau · 2 shared papers, 2017–2026 · strength 0.28
  13. Jean‐Luc Van Laethem · 7 shared papers, 2012–2016 · strength 0.23
  14. Yves Rinaldi · 1 shared paper, 2026 · strength 0.22
  15. Marc Hilmi · 1 shared paper, 2026 · strength 0.22
  16. Aurélien Lambert · 1 shared paper, 2026 · strength 0.22
  17. Romain Coriat · 1 shared paper, 2026 · strength 0.22
  18. F. Huguet · 4 shared papers, 2013–2016 · strength 0.19
  19. Iman El Hariry · 2 shared papers, 2020 · strength 0.17
  20. Fabienne Portales · 2 shared papers, 2020 · strength 0.17
  21. David Tougeron · 2 shared papers, 2020 · strength 0.17
  22. Pierre Michel · 1 shared paper, 2019 · strength 0.16
  23. Raphaël Maréchal · 5 shared papers, 2012–2015 · strength 0.13
  24. Pieter Demetter · 5 shared papers, 2012–2015 · strength 0.13
  25. P. Debourdeau · 2 shared papers, 2017–2019 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.